共 50 条
- [1] Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Berenson, James R.Cohen, AlexaSpektor, Tanya M.Lashkari, AshkanMackintosh, RoyBessudo, AlbertoRobinson, Michael OrenJhangiani, Haresh S.Gabrail, Nashat Y.Nakhoul, IbrahimKubba, Samir V.Neidhart, Jeffrey D.Maluso, TinaSwift, Regina A.Vescio, Robert A.
- [2] Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination RegimenEXPERIMENTAL HEMATOLOGY, 2022, 114 : 54 - 60Afari, JonathanSpektor, Tanya M.Turner, CarleyCohen, AlexaBessudo, AlbertoJhangiani, HareshGabrail, NashatKubba, SamirNeidhart, Jeffrey D.Eshaghian, ShahroozSwift, Regina A.Eades, Benjamin M.Kim, ClaraKim, SusannaVescio, RobertBerenson, James R.
- [3] Analysis of efficacy and safety of POM as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma pts refractory to a lenalidomide-containing combination regimen.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Berenson, James R.Cohen, AlexaSpektor, Tanya M.Lashkari, AshkanMackintosh, RoyBessudo, AlbertoRobinson, Michael OrenJhangiani, Haresh S.Gabrail, Nashat Y.Nakhoul, IbrahimKubba, Samir V.Neidhart, Jeffrey D.Maluso, TinaSwift, Regina A.Vescio, Robert A.Eshaghian, Shahrooz
- [4] EFFICACY AND SAFETY OF LENALIDOMIDE IN COMBINATION WITH DEXAMETASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMAHAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 625 - 625Canovas, A.Alonso, J. J.Barreiro, B.
- [5] Safety and Efficacy of Lenalidomide in Relapsed or Refractory Multiple MyelomaCLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2012, 6Alegre, AdrianVicuna, IsabelAguado, Beatriz
- [6] LENALIDOMIDE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMAANNALS OF ONCOLOGY, 2013, 24Okada, K.Okamoto, Y.Tsukamoto, T.Sugiura, H.Matsui, H.Ueda, T.Jo, T.Onishi, T.Kunitomi, A.Ueda, Y.
- [7] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myelomaBLOOD, 2017, 130 (10) : 1198 - 1204Paludo, JonasMikhael, Joseph R.LaPlant, Betsy R.Halvorson, Alese E.Kumar, ShajiGertz, Morie A.Hayman, Suzanne R.Buadi, Francis K.Dispenzieri, AngelaLust, John A.Kapoor, PrashantLeung, NelsonRussell, Stephen J.Dingli, DavidGo, Ronald S.Lin, YiGonsalves, Wilson I.Fonseca, RafaelBergsagel, P. LeifRoy, VivekSher, TaimurChanan-Khan, Asher A.Ailawadhi, SikanderStewart, A. KeithReeder, Craig B.Richardson, Paul G.Rajkumar, S. VincentLacy, Martha Q.
- [8] POMALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) PREVIOUSLY TREATED WITH LENALIDOMIDEHAEMATOLOGICA, 2020, 105 : 13 - 14Gomez, Hernando MartaGironella, MerceAbella, EugeniaCabezudo, ElenaMotllo, CristinaGarcia, AntoniSarra, JosepMostacedo, SilviaGranell, MiquelRosinol, Laura
- [9] A phase IIb trial of vorinostat in combination with lenalidomide and dexamethasone in patients with multiple myeloma refractory to previous lenalidomide-containing regimensBRITISH JOURNAL OF HAEMATOLOGY, 2017, 176 (03) : 440 - 447Sanchez, LarysaVesole, David H.Richter, Joshua R.Biran, NoaBilotti, ElizabethMcBride, LauraAnand, PalkaIvanovski, KristinSiegel, David S.
- [10] Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple MyelomaBLOOD, 2014, 124 (21)Plesner, TorbenArkenau, Hendrik-TobiasLokhorst, Henk M.Gimsing, PeterKrejcik, JakubLemech, CharlotteMinnema, Monique C.Lassen, UlrikLaubach, Jacob P.Ahmadi, TahamtanYeh, HowardGuckert, Mary E.Feng, HuaibaoBrun, Nikolai ConstantinLisby, SteenBasse, LindaPalumbo, AntonioRichardson, Paul G.